N-Acetyl Cysteine Plus Behavioral Therapy for Nicotine Dependent Pathological Gamblers

Conditions

Gambling | Tobacco Use Disorder

What is the purpose of this trial?

The objective of this application is to examine whether, given its mechanism of action, the dietary supplement, N-acetyl cysteine (NAC) will reduce both tobacco use and pathological gamblers (PG) symptoms in nicotine dependent pathological gamblers.



Participation Guidelines

Age:
18 Years - 75 Years
Gender:
Both

Click here for detailed information about who can participate in this trial.


Sponsor:
National Institute on Drug Abuse (NIDA)
University of Minnesota - Clinical and Translational Science Institute
Yale University
Dates:
September 2009
Last Updated:
February 23, 2012
Study HIC#:
0909005714

Clinicaltrials.gov ID: NCT00967005